Actively Recruiting

Phase 2
Age: 18Years - 75Years
FEMALE
NCT03025477

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

Led by Groupe Hospitalier Diaconesses Croix Saint-Simon · Updated on 2021-02-11

84

Participants Needed

7

Research Sites

834 weeks

Total Duration

On this page

Sponsors

G

Groupe Hospitalier Diaconesses Croix Saint-Simon

Lead Sponsor

G

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborating Sponsor

AI-Summary

What this Trial Is About

CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.

CONDITIONS

Official Title

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer

Who Can Participate

Age: 18Years - 75Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed advanced (FIGO stage III or IV) invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer
  • Initial intervention: debulking surgery or diagnostic surgery within 3 weeks before inclusion
  • Age 18 to less than 75 years old
  • ECOG performance status 2 or less before surgery (ECOG 1 or less and Lee score less than 6 for patients over 70 years old)
  • Adequate blood counts within 14 days before inclusion: neutrophils greater than 1500/mm3, platelets greater than 150,000/mm3
  • Creatinine clearance MDRD 60 mL/min or higher
  • Registered in a national health care system (including CMU)
  • Signed and dated informed consent
Not Eligible

You will not qualify if you...

  • FIGO stage IV extra-abdominal disease except lymph nodes and pleural invasion
  • Previous chemotherapy for ovarian cancer
  • Left ventricular ejection fraction less than 50% before chemotherapy
  • Other invasive cancer within the past 5 years except fully resected basal or squamous cell skin carcinoma
  • Use of prophylactic phenytoin or live attenuated viral vaccines such as yellow fever vaccine
  • Known hypersensitivity to any study drug components
  • Lack of motivation or ability to follow study requirements and constraints
  • Pregnancy or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Centre Georges François Leclerc

Dijon, France

Actively Recruiting

2

Institut Hospitalier Franco-Britannique

Levallois-Perret, France

Actively Recruiting

3

Groupe Hospitalier Diaconesses Croix Saint Simon

Paris, France

Actively Recruiting

4

Hôpital Saint Antoine

Paris, France

Actively Recruiting

5

Hôpital Poissy Saint Germain

Poissy, France

Actively Recruiting

6

CHU Poitiers

Poitiers, France

Actively Recruiting

7

Centre Hospitalier Senlis

Senlis, France

Actively Recruiting

Loading map...

Research Team

R

Richard VILLET, MD

CONTACT

D

Delphine COCHEREAU, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer | DecenTrialz